Astellas Pharma ((ALPMF)) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Astellas Pharma is conducting a Phase 1 clinical study titled A Phase 1 Study of ASP3082 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation. The study aims to evaluate the safety and tolerability of ASP3082 in adults with advanced solid tumors that have the KRAS G12D mutation, a significant target in cancer treatment.
The study is testing ASP3082, both as a standalone treatment and in combination with other drugs like cetuximab, to determine effective dosing levels. ASP3082 is administered through intravenous infusion, targeting solid tumors with a specific genetic mutation.
This open-label, non-randomized study follows a sequential intervention model. It is designed to assess treatment efficacy, with no masking involved, meaning both participants and researchers know the treatment being administered.
The study began on May 16, 2022, with the primary completion date yet to be announced. The latest update was submitted on September 18, 2025, indicating ongoing recruitment and progress.
The study’s progress could influence Astellas Pharma’s stock performance positively, as successful results may enhance investor confidence. This development is particularly relevant in the competitive oncology market, where advancements in targeted therapies are highly valued.
The study is currently ongoing, with further details available on the ClinicalTrials portal.